Enhanced Pharmaceutical Compositions for Viral Infections
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses novel pharmaceutical compositions comprising sulfur-containing nucleosides conjugated to lipids or sphingolipids, with added stabilizing agents, permeation enhancers, or mucoadhesive agents, to improve the treatment of viral infections.
Background and Problem Solved
The original patent disclosed pharmaceutical compositions comprising sulfur-containing nucleosides, but these compositions had limitations in terms of shelf life, stability, and bioavailability. The new inventive concept addresses these limitations by introducing conjugate compounds linked to lipids or sphingolipids, which enhance the delivery and efficacy of the nucleoside analogs.
Detailed Description of the Inventive Concept
The new pharmaceutical compositions comprise conjugate compounds of Formula Im, where the conjugate compound is linked to a lipid or sphingolipid via a phosphorus oxide. The compositions further include a stabilizing agent, such as antioxidants, chelating agents, or pH buffers, to enhance the shelf life and stability of the composition. Additionally, the compositions may include a permeation enhancer to facilitate the delivery of the conjugate compound across the cell membrane, or a mucoadhesive agent to enhance the bioavailability and retention of the composition at the site of infection.
Novelty and Inventive Step
The new inventive concept introduces the conjugation of sulfur-containing nucleosides to lipids or sphingolipids, which is a novel and non-obvious improvement over the original patent. The addition of stabilizing agents, permeation enhancers, or mucoadhesive agents provides further enhancements to the composition, making it more effective and efficient in treating viral infections.
Alternative Embodiments and Variations
Other embodiments of the inventive concept may include varying the type of lipid or sphingolipid used, or modifying the phosphorus oxide linker. Additionally, the compositions may be formulated for specific routes of administration, such as oral, injectable, or topical.
Potential Commercial Applications and Market
The enhanced pharmaceutical compositions have significant commercial potential in the treatment of viral infections, particularly in the areas of antiviral therapy and vaccine development. The target market includes pharmaceutical companies, research institutions, and healthcare providers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically nucleoside analog drug design and viral infection treatment, with expertise in chemical conjugation techniques, drug formulation, and pharmaceutical composition optimization
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical chemist with advanced degree, experience in nucleoside analog synthesis, understanding of drug delivery mechanisms, and knowledge of chemical modification strategies for improving drug performance
Obviousness Rationale
A person skilled in the art would recognize that adding stabilizing agents, permeation enhancers, and mucoadhesive agents to the existing nucleoside conjugate composition represents a predictable optimization strategy. The source patent's foundational work on sulfur-containing nucleoside conjugates provides a clear technical framework for incremental improvements in pharmaceutical delivery and stability. These modifications represent standard pharmaceutical engineering techniques that would be obvious to implement for enhancing drug performance.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,560 |
|---|---|
| Title | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections |
| Assignee(s) | Emory University |